AACR22: Amgen reveals new long-term data for Lumakras, looking to keep pressing market advantage over Mirati

NEW ORLEANS — Amgen attempted to further pull away from Mirati Therapeutics in the KRAS space, touting a new batch of long-term non-small cell lung cancer data at AACR for its approved drug Lumakras. In a pooled dataset of 172 NSCLC patients from its Phase I and Phase II studies,…

Click to view original post